A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma.
Mrinal M GounderEvan RosenbaumNian WuMark A DicksonTahir N SheikhSandra P D'AngeloPing ChiMary Lou KeohanJoseph P ErinjeriCristina R AntonescuNarasimhan AgaramMeera R HameedMoriah MartindaleRobert A LefkowitzAimee M CragoSam SingerWilliam D TapNaoko TakebeLi-Xuan QinGary K SchwartzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The combination of RO4929097 plus vismodegib was generally well tolerated. Although accrual to this study was not completed, vismodegib did not meaningfully enhance the clinical efficacy of RO4929097 in an unplanned analysis. GSIs and GSIs plus vismodegib can inhibit intratumoral Notch and downstream phosphorylated Akt signaling.